<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152382</url>
  </required_header>
  <id_info>
    <org_study_id>17218</org_study_id>
    <secondary_id>J1A-MC-KDAC</secondary_id>
    <nct_id>NCT04152382</nct_id>
  </id_info>
  <brief_title>A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis</brief_title>
  <official_title>A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine how safe and how well tolerated LY3462817 is when&#xD;
      given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is&#xD;
      in the bloodstream and how long the body takes to get rid of it. The study will last up to&#xD;
      one year and one month for each participant. As part of protocol addendum, this study is&#xD;
      additionally evaluating the safety and tolerability of LY3509754 in participants with&#xD;
      psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how&#xD;
      long the body takes to get rid of it. The addendum will last up to 12 weeks for each&#xD;
      participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study is suspended due to safety review.&#xD;
  </why_stopped>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">July 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to LY3462817 and LY3509754</measure>
    <time_frame>Baseline through Final Follow-up (up to Week 52 for LY3462817 &amp; up to Week 16 for LY3509754)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Average Concentration (Cave) of LY3462817 and LY3509754</measure>
    <time_frame>Baseline through Final Follow-up (up to Week 52 for LY3462817 &amp; up to Week 16 for LY3509754)</time_frame>
    <description>PK: Cave of LY3462817 and LY3509754</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>LY3462817 - Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3462817 administered as IV infusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as IV infusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3462817 - Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3462817 administered as SC injections. (SC administration is discretionary/optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as SC injections. (SC administration is discretionary/optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3509754</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3509754 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3462817 - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3462817 - Intravenous (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3462817 - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3462817 - Subcutaneous (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3509754</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3509754</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have been diagnosed with psoriasis for at least 6 months&#xD;
&#xD;
          -  Participants must have active psoriasis plaques&#xD;
&#xD;
          -  Participants must be willing and able to have skin biopsies (small samples of skin&#xD;
             removed for testing)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have received certain medications for psoriasis that are applied&#xD;
             to the skin within 14 days prior to baseline (Day 1)&#xD;
&#xD;
          -  Participants must not have received certain oral or injectable medications or light&#xD;
             therapy for psoriasis within 4 weeks prior to baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Associates - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Dermatology and Laser Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avita Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermDox Centers for Dermatology</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simcoderm Medical &amp; Surgical Dermatology Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Health</name>
      <address>
        <city>Cobourg</city>
        <state>Ontario</state>
        <zip>K9A 0Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/azmsPbmvZOOmiS1aMi7nO</url>
    <description>A Safety Study of LY3462817 in Participants With Psoriasis</description>
  </link>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

